Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
Kedor C, Listing J, Zernicke J, Weiß A, Behrens F, Blank N, Henes JC, Kekow J, Rubbert-Roth A, Schulze-Koops H, Seipelt E, Specker C, Feist E. Kedor C, et al. Among authors: feist e. Ann Rheum Dis. 2020 Aug;79(8):1090-1097. doi: 10.1136/annrheumdis-2020-217155. Epub 2020 May 13. Ann Rheum Dis. 2020. PMID: 32404342 Free PMC article. Clinical Trial.
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Burmester GR, et al. Among authors: feist e. Ann Rheum Dis. 2011 May;70(5):755-9. doi: 10.1136/ard.2010.139725. Epub 2010 Dec 27. Ann Rheum Dis. 2011. PMID: 21187298 Free PMC article. Clinical Trial.
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.
Iking-Konert C, Aringer M, Wollenhaupt J, Mosch T, Tuerk S, Feist E, Burmester GR. Iking-Konert C, et al. Among authors: feist e. Ann Rheum Dis. 2011 Nov;70(11):1986-90. doi: 10.1136/ard.2011.152678. Epub 2011 Aug 29. Ann Rheum Dis. 2011. PMID: 21875873 Free PMC article. Clinical Trial.
Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, West CR. Balanescu AR, et al. Among authors: feist e. Ann Rheum Dis. 2014 Sep;73(9):1665-72. doi: 10.1136/annrheumdis-2012-203164. Epub 2013 Jul 12. Ann Rheum Dis. 2014. PMID: 23852695 Clinical Trial.
Rheumatoid arthritis: an antigenic chameleon.
Feist E, Steiner G. Feist E, et al. Ann Rheum Dis. 2014 Oct;73(10):1753-4. doi: 10.1136/annrheumdis-2014-205307. Epub 2014 Jun 6. Ann Rheum Dis. 2014. PMID: 24906638 No abstract available.
220 results